Pediatrix Medical Group, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Pediatrix reported Q2 2026 net revenue of $487.8M (up 4.0% YoY) and net income of $39.8M ($0.49 diluted EPS), with Adjusted EBITDA of $76.4M. Same-unit revenue grew 1.9% despite patient volume declining 2.1%, offset by 4.0% reimbursement gains from improved collections and favorable payor mix shift (commercial up 135 bps). The company reaffirmed full-year 2026 Adjusted EBITDA guidance of $280M–$300M. Weighted average diluted shares fell to 81.4M (from 85.5M YoY) due to $42.7M in Q2 repurchases; cash declined to $288.9M (from $375.2M year-end) as the company deployed capital.
Why this rating
Modest organic growth (~2%), reimbursement tailwinds, but offset by volume headwinds and higher costs. Guidance reaffirmed. Routine quarterly results—no deal, no major change, cash decline modest relative to ~$900M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.